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KEY TO ABBREVIATION
HLA - Human leukocyte antigen
HPA - Human platelet antigen
        ELISA - Enzyme linked immunoassay 
GP - Glycoprotein 
AML - Acute myeloid leukemia
 
ALL - Acute lympoblastic leukemia 
ADP - Adenosine Diphosphate 
ATP - Adenosine tri phosphate 
PIET - Platelet immunofluoresence test 
PNPP - p- nitrophenoyl phosphate 
MDS - Myelodysplastic syndrome
VWF - Von Willebrand disease 
RDP - Random donor platelet
SDP - Single donor platelet
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INTRODUCTION
Transfusion plays an important role in the management of patients with hematological 
malignancies and disorders.  Patients  during the induction chemotherapy may need multiple 
transfusion of platelets and red cells and may develop refractoriness; platelet count increment 
deteriorate  even  after  adequate  dose  of  platelets  are  transfused.  Although  several  studies 
reported non-immunological factors like fever, Splenomegaly, septicemia and severe bleeding 
are responsible for refractoriness in some patients, no specific reasons can be found. This raises 
the suspicion of platelet antibodies for the cause of refractoriness. Till now in many studies, the 
presence of HLA and platelet specific antibodies were found to be between 10%-60%in the 
patients who were treated with multiple transfusions. 
Non- immunological factors in impairment of post transfusion platelet count increment 
are difficult to influence, but refractoriness due to platelet alloimmunization can be prevented 
and treated by using HLA and HPA matched transfusion, platelet cross matching by ELISA, 
leukocytes filtered and irradiated transfusions. This possibility paved way for the development 
of immunological techniques to detect platelet alloantibodies against HLA class 1 antigens, 
platelet glycoproteins and human platelet antigens. 
REVIEW OF LITERATURE
 
Bajpai M, et al tested for antibodies in 50 patients before transfusion and 3-4 weeks 
after  multiple  transfusion,  found 66% with  antiplatelet  antibodies  of  which  71% were  not 
responding to transfusion. 26% of antibodies negative patients were non responsive. (National 
medical journal of India 2005 may 18 issues 3, 134- 6)
Los Sc, et al did a study on 60-thalassemia patients and found 19 with (31%) HLA, 
13with (22%) with both HLA and HPA antibodies and 1with (2%) HPA antibodies. The follow 
up study showed that 7 patients developed HLA antibodies and 1 lost the antibodies. 9 patients 
developed  HPA antibodies  and  12  lost  at  least  one  HPA antibodies.  He  concluded  RBC 
transfusion can induce alloimmunization and   HLA antibodies are sustain longer than HPA 
antibodies. (Transfusion 2005 may 45, I 5, 761-5)
 
Kiefel v  et  al  tested  252  patients  with  hematological  malignancies,  Hematological 
disorders with thrombocytopenia, MDS, chronic Myeloproliferative disorders and found 108 
with (42%) HLA antibodies and 20 with (8%) HPA antibodies positive. He observed 53% of 
female patients with previous pregnancy and 23% without previous pregnancy were positive 
for antibodies. (Transfusion 2001 June 41(6) 776- 70)
According to  Cristina sanz studies 3.8% of the  HLA alloimmunization patients  are 
positive  for  HPA  antibodies  glycoprotein  iib/iiia  and  anti  HPA-5b  and  concluded  HPA 
antibodies in HLA immunized patients is very low and can be searched only when other causes 
are ruled out. (Transfusion 2001 volume 41(6) 762-5)
Lo sc et al studied on 103 patients and found 40 are platelet reactive antibodies positive 
of  which 22 had both HLA and HPA antibodies,  12 had HLA alone and 5 had only HPA 
antibodies. 81% of platelet specific antibodies were found in HLA alloimmunized patients of 
which frequently found were glycoprotein ia/iia and iib/iiia. (J formos med assoc 2000 dec; 99 
(12): 902-5)
Pereira j et al observed alloimmunization in 17% and 2% due to HLA and HPA in adult 
patients  and  no  children  were  reported  positive  for  antibodies  after  every  four  weeks  or 
whenever the 1 hr corrected count increment for platelet transfusion was lower than 5000. (Rev 
med chill 1997 Nov; 125(11): 1305-12)
40 patients had at least one episode of refractoriness out of 145 patients who received 
more  than  three  single  donor  platelet  transfusions,  in  whom  15  refractory  patients  show 
alloantibodies . 7 patients got inadequate transfusion response due to Alloimmunization alone 
and 8 due to alloimmunization and fever Or sepsis ( Legier TJ et al. Ann hematol 1997 apr; 
74; 4; 185-9)
Taaning E et al studied 117 heart surgery patients for HLA antibodies and found 21 
were positive, 18 were negative before transfusion and 2 cases positive for platelet specific 
antibodies who received multiple transfusion .(vox sang 1992; 72; 4; 238-41)
Pan reactive antibodies against Gpib/ix has similar frequency as that of Gpiib/iiia and 
Gpia/iia always in combination with above once. Most HPA antibodies were directed against 
HPA-Ib and –5b in Kurz m et al  (Br j of hematology 1996; dec; 95; 3; 564-9)
Yan et al screened antibodies for HLA class I and GP iib/iiia by using GTI MACE 1, in  
which 1.25% Glycoprotein antibodies and 75% for HLA antibodies are positive. ( Journal of 
thrombosis & hemostasis 2005 vol 3,sup 1)
Uhrynowska  M  et  al screened  104  multi-transfused  patients  were  31%  are 
alloantibodies positive of which HLA alloimmunization is 20%, HPA - 1a, 2b, 3a and 5b in less 
than 4% and 6% of GP ii/iiia. Eur jor of hematol 1996 apr 56; 4; 248-51.
Hogge DE et al concluded that alloimmunization and refractoriness is 37% in pediatric 
patients and low in acute myelogeneous Leukemia. The detection of antibodies predicts poor 
response to random donor platelet  transfusion,  but most such patients  improved with HLA 
matched platelets. ( Transfusion 1995; aug; 35; 8; 645-52)
Novothy VM et al published HLA alloimmunization in high risk negative patients is 
2.7%(3 of 112) and 31%16 of 54) in positive risk patients. 22% positive for alloimmunization 
when stored platelet transfused by bed side filtrations. (Blood vol 85; 7 april 1995; 1736-41)
Chow MP et al  found disappearance of platelet antibodies during follow up period by 
50% of positive cases of HPA and 10% in HLA antibodies cases. Acta hematol 1994; 92; 2; 57-
60.
In 59 multi transfused patients treated for hematological disorders, 10(17%) were found 
to be positive for   human platelet specific antibodies. 6 patients with HPA-1b, 3 with HPA-3a, 
2 with HPA-1b and 3a and 1 with HPA-5a. ( Schnaidt m et al Beitr infusionsther transfusion 
medicine 1994; 32; 240-3) 
Ishida A et al studied platelet transfusion efficacy after hematopoietic transplantation in 
42 patients and found platelet alloimmunization due to HLA and HPA antibodies is 17% and 
14%  in  allogeneic  and  autologous  transplantation  patients  with  platelet  transfusion. 
(Transfusion, 1998;sep; 38; 9; 839-47)
HLA antibodies disappear in 6 patients who discontinued transfusion and 8 patients after 
treating  with  matched  and  leukocyte  reduced  platelet  transfusion  out  of  40  patients 
alloimmunized.( Murpy MF et al Br J of hematol 1987;nov; 67; 3; 255-60) 
Kurz M et al reported MAIPA assay is sensitive method than LCT in  detecting platelet 
reactive  HLA  antibodies  (24%vs  8%).  (Br  j  of  Hematology  Volume  95(3-I), December 
1996, pp 564-569)
Frequency  of  alloimmunization  in  acute  non-lymphocytic  leukemia  is  lower  than 
aplastic anemia and no relationship between Alloimmunization development and number of 
platelet transfused according to Nozaki H et al.  (Tokai J exp clin med1986; aug; 11; 3; 201-4)
Mc Grath K et al study states that platelet recovery at 1hr and 20hr post transfusion 
was  not  significantly  reduced  in  the  presence  of  platelet  specific  antibodies.  (  Br  j  of  
hematology 1988;mar; 63 3; 345-50)
HLA  homozygous  allies  have  high  prevalence  of  platelet  alloimmunization  and 
antibodies to certain specificities like HLA B60 and 75 are in higher rate in  Chop Mp et al. 
(Zhongua yi xue zazhi 1993 may; 51; 5; 329-32)
85% of multiple RBC transfused patients are alloimmunization to HLA or HPA Antigens 
in Friedson DF et al.  (Blood 1996;Oct; 88; 8; 3216-22)
Chop MP et al, development of platelet alloimmunization from initial transfusion 
may vary from 10-190days and 40% who did not develop antibody will never develop 
later. ( Zhongua yi xue za zhi 1991;apr;47;;4;237-41)
 Mac Pherson BR concluded that 79% antibodies found inMultiple transfusion patients 
are directly against public HLA Antigens. (Ann clin lab sci 1986 Jan; 16; 1; 38-44)
Wernet D et al  studied 388 patients for HLA and HPA antibodies of which 27 
showed cold reacting auto antibodies and lymphocytic restricted reaction in 20 patients. 
(Vox sang 1993; 65; 2; 108-13)
28% (8 out of 29 patients) of patients developed HLA antibodies after ventricular Assist 
device support and need of more transfusion in post Operative by Mc kenna DH et al. (J heart 
lung transplant 2002;nov; 21; 11; 1218-24)
Presence of platelet antibodies was significantly associated with post transfusion fever in 
Masanoir S et al. (Japanese J of clinical oncology 1977; 7; 35-43)
Splenectomized  patients  have  greater  platelet  increment  than  normal  sized  spleen 
patients at 1hr and 24hr after transfusion in Sherrill et al. (Blood may 2005; 105; 10; 4106-15)
Docoteau et al.  Only 2.3%of ALL children’s presented with platelet antibodies than 
31% of AML. (J of pediatric hematology oncology 1995; nov; 17; 4; 306-10)
Godeau B et al studied 50 patients who received multiple platelet transfusion, only 2 
patients had HPA antibodies of which 1 showed poor platelet recovery and 11 were positive for 
Para -formaldehyde dependent platelet with out refractoriness.( Br J of Haematol 1992;jul; 81; 
3; 395-400)
Lam CP published A2, A11, B16 and B60 are specificities of the identified antibodies in 
alloimmunization patients.( Zhon yi xue za zhi 1992; Dec; 5; 6; 329-42)
PLATELETS
PLATELETS STRUCTURE & FUNCTION  : -  
Platelets  are  small,  anucleated fragments  measuring 2micro  m in diameter  and with 
volume of 8-10 FL. The platelets vary in number, size, density, age and apparent physiologic 
effectiveness. The life span of the platelet is around 8-12 days and turnover is estimated to be 
1.2 to 1.5x 10*11 cells per day. (Wintrobes  clinical hematology 11th edition.)  
It contains membranes, microtubules and granules. The external membrane composed of 
proteins, glycoproteins and mucopolysaccharides, which play major role in mediating platelet 
response to stimuli and in expressing antigenic characteristics. The internal membrane contains 
sub membranous microfilaments, which maintain the platelet discoid shape.
The  microtubules  are  an  enclosed  system containing  ionized  calcium,  enzymes  and 
actin, myosin filaments. These are involved in motor activities such as pseudopodia movements 
and secretion.  
The granules in organelle zone are i. Delta granules like ADP, ATP and serotin etc ii.  
Alpha granules like platelet specific proteins, platelet factor 4, fibrinogen, factor v etc. these 
granules are found dispersed in cytoplasm of platelet, and on stimulation granules are released 
into extra cellular environment. (Anderson and ness, scientific basis of transfusion medicine.) 
                             
PLATELET ANTIGENS: -
Platelets contain variety of antigens on the cell surface, 
1) ANTIGENS FOUND ONLY ON PLATELETS
Platelets  Specific  antigens  arise  as  a  result  of  polymorphisms of  platelet  membrane 
glycoprotein.  These  membranes  contain  number  of  glycoproteins  that  contribute  to  the 
immunogenic make up of the platelet. (This HPA nomenclature system was adopted in 1990 
Vodem Borne AE, Decary F 1990).
The intergrins are membrane glycoprotein heterodimers, consisting of non -covalently 
associate alpha & beta subunits. There are 17 alpha & 8 beta subunits, with the possible alpha 
beta combination led to discover 23 different intergrins in humans. Two platelet membrane 
receptors  that  are  seen  prominently  in  antigenic  profile  of  platelets,  the  cohesion  receptor 
αiibβ3 and the collagen receptor α2β1 are intergrins. The platelet intergrins αiibβ3 are initially 
called  as  glycoprotein  iib/iiia  which  helps  in  platelet  aggregation  (The  common  cohesive 
pathway) by binding of adhesive proteins fibrinogens & von wille brand factor (vwf).  The 
platelet  collagen  receptor  α2β1,  intergrins  is  initially  called  as  Gp  ia/iia,  which  plays  a  
fundamental role in adhesion of blood platelets to both fibrillar (types i, ii, iii and v) and non 
fibrillar  (type  iv,  vi,  vii,  viii)  collagens.  Third  receptor  complex Gp ib-ix-v  is  a  heptamer 
contains 1 molecule of glycoprotein v and 2 molecules of each glycoprotein Ib, IIb and ix. This 
complex  is  a  receptor  for  vwf.  Platelet  glycolipids  plays  important  role  in  structural  and 
functional characteristics of platelet  membrane but less know. Lactosyl ceramide represents 
major glycolipids in platelet membrane.
The HPA Nomenclature categorizes all  antigens expressed on the platelet membrane, 
except those encoded on genes of major histocompatability complex. HPAs are grouped in 
systems  based  on  having  all  antibodies  defining  a  given  alloantigen  and  its  antithetical 
alloantigen. To date , 24 platelet specific alloantigen (tab 1) have been defined of which 12 are 
grouped  into  six  biallelic  systems  and  for  the  remaining  12  alloantibodies  are  yet  to  be 
discovered ( Metcalfe P el al 2003).              
                                                           Table- 1  
Human platelet antigens
                              
System Antigen Glycoprotein CD
HPA-1 HPA-1a GPIIIa 61
HPA-1b GP
HPA-2 HPA-2a GPIb  42b
HPA-2b GP
HPA-3 HPA-3a GPIIb  41
HPA-3b GP
HPA-4 HPA-4a GPIIIa  61
HPA-4b GP
HPA-5 HPA-5a GPIa  49b
HPA-5b GP
HPA-6bw GPIIIa 61
HPA-7bw GPIIIa 61
HPA-8bw GPIIIa  61
HPA-9bw GPIIb 41
HPA-10bw GPIIIa 61
HPA-11bw GPIIIa 61
HPA-12bw GPIa 42c
HPA-13bw GPIa 49b
HPA-14bw GPIIIa 61
HPA-15 HPA-15a CD109 109
HPA-15b
HPA-16bw GPIIIa 61
Platelet antigens are also present in other cells, HPA IA has been detected on vascular smooth 
cells & fibroblasts, and HPA-5 also expresses on activated T cells.
2) HLA ANTIGENS ON THE PLATELET SURFACE
The principal  antigens  shared  by platelets  and lymphocytes  are  HLA class  1  and 2 
Antigens, where platelet are the major source of class I HLA antigens. The studies suggested 
that these antigens were not only firmly embedded in the membrane and but also absorbed from 
the surrounding plasma (kao KJ et  al  1988 and sugawara S et  al  1987).  Recent  studies 
showed that most class 1 HLA molecules on platelets are integral membrane proteins, which 
are  persisting  from  the  megakaryocyte  stage  of  development.   Platelet  process  m  RNA 
encoding HLA class 1 molecules, which are capable of synthesizing HLA molecules (Mollision 
11TH Edition). Peptides of the HLA molecules derived from the megakaryocyte platelet specific 
GP ix. The number of HLA molecules expressed on the platelet surface various from 15,000-
1,20000. (HLA class II antigens are not detectable on platelets but HLA -DR antigens can be 
induced on platelets surface by stimulation with cytokines Harvey G. Klein & David J. Anstee. 
Mollision 11th edition)
3) RED CELL ANTIGENS ON PLATELET
Red cell antigens ABH, Lewis, I, & P are also expressed on platelets. These antigens are 
intrinsic and others are absorbed from plasma. This antigen could explain reduction in platelet 
recovery when ABO incompatible platelets are transfused. The ABH and other red cell antigens 
are expressed on many integral platelet membrane Glycoproteins including GP II b, GP IIIa, 
GD IV, V, GP Ib /IX & GP ia\ IIa.( Curtis BR et al 2000, Santoso S et al 1991) 
PLATELET ANTIGEN ALLOIMMUNIZATION: -
Alloimmunization is an immunological state referring to immune system’s response to 
foreign antigens most often involving the production of antibodies directed at the antigens. The 
platelet  alloimmunization  leads  to  clinical  condition  PLATELET  REFRACTORINESS  in 
which  a  patient  does  not  achieve  the  anticipated  platelet  count  increment  from a  platelet  
transfusion. An immune or a non-immune condition may cause refractoriness.
I) IMMUNOLOGIC BASIS OF PLATELET REFRACTORINESS
1) ALLOIMMUNIZATION TO HLA ANTIGENS
Recent  practice  of  prophylactic  multiple  platelet  transfusion,  results  in  decreasing 
effectiveness in many patients due to induction of alloantibodies to HLA class I, HPA and other 
Red cell antigens. HLA Antibodies are not naturally occurring Antibodies and develop due to 
pregnancy and Blood Transfusion. Development of HLA antibodies occur as early as 10 days 
after primary exposure or 4 days after secondary exposure in patients who had been  multiple 
transfused or multiple pregnancy( Rossi’s principles of transfusion medicine 3rd edition).The 
HLA  alloimmunization  is  related  to  underlying  diseases,  immunosuppressive  effect  and 
immune responsiveness.  There is some general agreement that primary alloimmunization to 
HLA Antigens  is  unlikely  to  occur  before  3-4 weeks after  the  first  transfusion  in  patients 
receiving  multiple  transfusions,  and  antibodies  detected  sooner  may  be  due  to  secondary 
immune response. The major immunizing source of HLA antigens in transfused platelets and 
red cells is the donor leukocytes. In some patients presence of HLA class I Antibodies does not 
produce  refractoriness  to  platelet  transfusion  due  to  low  frequency  HLA  antigens  and 
antibodies against them will not react with the platelet of random donors. Some donor antigens 
express  so  weakly  that  makes  platelet  to  survive  normally  even  though  patients  have 
antibodies.  Further  more  patients  with  HLA  class  I  antibodies  may  form  antiidiotype 
antibodies,  which  will  inactivate  the  class  I  antibodies.  In  significant  percentage  of 
alloimmunized patients, antibodies disappear or decline with time. (Mollisons 11th edition)
2) ALLOIMMUNIZATION TO PLATELET –SPECIFIC ANTIGENS
HPA Antibodies have been discovered in Neonatal alloimmune thrombocytopenia, 
post  Transfusion Purpura and multiple transfusions and are rare cause of transfusion 
refractoriness. Alloimmunization to high- frequency platelet specific antigens leads to a 
major  challenge  in  finding  compatible  platelets.  Patients  may  also  from antibodies 
against entire platelet glycoproteins molecule V, Ib, IIb-IIIa etc.
3) ALLOIMMUNIZATION TO BLOOD GROUP ANTIGENS
Platelets have weak expression of antigen A& B. Donor with strong A or B may 
develop refractoriness after transfusion of ABO incompatible platelets. This is mainly 
due to the anti-A or B substance in patients react with donor ABH substance.
II) NON-IMMUNE PLATELETS REFRACTORINESS: -
Alloimmunization is not only the major cause of  refractoriness, but non immune factors 
like Splenomegaly, fever, infection, DIC, hepatic dysfunction and veno-occlusive disease and 
marrow transplantation also play a role.  Platelet refractoriness has been reported with number 
of medication Antibiotics, Amphotercin, GM-CSF and other interferon’s.
INVESTIGATIONS FOR PLATELET ANTIBODIES:
Tests are based on the detection of platelet bound Ig. The following are the tests for the 
detection of platelet antibodies,
 
1) Platelet immunofluoresence test, (Von dem borne 1978)
2) The enzyme-linked immunosorbent assay (Tata and co workers 1977).
3) Mixed red cell adherence assay and
4) Monoclonal antibody specific immobilization of platelet antigens.
         
THROMBOCYTOPENIA 
It is defined as a subnormal number of platelets in the circulatory blood. It occurs due to 3 
processes;
A. Disorders of platelet production (decrease production or dysfunction).
B. Platelet sequestration.
C. Platelet destruction.
Decrease production occurs due to toxic (chemotherapy agents,  ethanol,  radiation 
and ganciclovir etc.) or pathological in suits damage megakaryocytes in the bone marrow 
like primary and secondary leukemias, myelodysplastic syndrome, met static carcinomas.   
Dysfunctional platelets are normal in number, but their function is abnormal. It is 
caused by congenital disease like glanzmann thrombasthenia, Bernard soulier syndrome, 
platelet type von wille brand disease and gray platelet syndrome etc and acquired causes 
due  to  medication,  uremia,  cardiopulmonary  bypass  and  hematological  disorders  and 
malignancy.
Hypersplenism due to any causes like portal  venous hypertension, liver cirrhosis, 
infection, malignances lead to pooling of platelets in the spleen and increase sequestration. 
Platelet destruction occurs mainly due to immune mediated include drug induced, platelet 
auto or allo antibodies, ITP and non immune causes like DIC, TTP, microbial infection, 
trauma, invasive surgery, burns and obstetric conditions. (Rossi’s   platelet transfusion )
Thrombocytopenia  is  classified  into  three  types  depending  on  the  count  as  ( 
Lawrence D Petz, clinical practice of transfusion medicine 2nd Edition) 
1.  Severe          –          5,000-20,000/uml.
2.  Moderate      –        20,000-50,000/uml.
3.  Mild             –        50,000-1,00,000/uml.
PLATELET TRANSFUSION: -
Early in 20th century, fresh whole blood was the only source of viable platelets, which 
was replaced in 1960-1970 by concentrates separated from whole blood after development 0f 
plastic bags. It  is mainly used to treat or prevent bleeding in the patients with low platelet 
count. 
Since platelet express ABO antigens, ABO compatible transfusion appears to give better 
results than incompatible once (Duquesnoy RJ et al 1979, Heal JM et al 1987). Small amount 
of red cells are contaminated in both random donor platelet (less than .5ml of RBC) and single 
donor  platelets  (less  than  5ml  of  RBC).  When Rh-positive  donors  are  transfused into  Rh-
negative patients, there is 14% incidence of Rh alloimmunization, which can be prevented by 
giving Rh immuno globulin intravenously.  
The decision to transfuse platelets falls into two categories I)Treatment for bleeding due 
to thrombocytopenia irrespective of platelet count, and II)Prophylaxis for patients having count 
less  than  20,0000/µml  (  christopher  D  Hillyer  et  al Hand  book  of  pediatric  transfusion 
medicine). 
The dose of platelet for transfusion is determined by number of platelet in single donor 
platelet (3x1011/unit) and random donor platelet (5.5x1010/unit). Each unit of RDP increases 
5000-10000/µml  in  a  70kg  adult  and  50,000-60,000  in  SDP (Denise  M  Harmening 4TH 
Edition).  Dosing  is  done  on  the  post  transfusion  platelet  increment,  the  higher  the  post 
transfusion platelet increment, longer the interval between the transfusions.
MANAGEMENT OF ALLOIMMUNIZED PATIENTS: -
The refractory status, which fails to random donor platelet transfusion, ranges from 13% 
to  100% (Pamphilon  DH et  al 1989)  of  patients  receiving  multiple  transfusions.  Several 
methods  were  considered  to  treat  such  patients  with  1)  fresh  blood,  single  donor,  ABO 
compatible  platelet  transfusion.  2)  HLA matched  platelet  transfusion  according  to  cross 
reactive  associations  grade.  3)  Platelet  cross  matching  by  ELISA,  PIFT.  4)  Treating 
alloimmunity status by IV immunoglobulin and 5) other factors like using vinblastine loaded 
platelet transfusion, treating with cyclosporin A, Immunoadsorption, plasmapheresis which all 
have limited successes.
Classification of donor/recipient pairs on the basis of HLA match
CROSS REACTIVE ASSOCIATIONS
A All 4 antigens in donor identical to those in recipient
BIU Only 3 Ag detected in donor; all present and identical to recipient 
BIX 3  donor  Ag  identical  to  recipient;  4th Ag  cross  reactive  with 
recipient 
B2U Only 2 Ag detected in donor; both present and identical in recipient
B2UX Only 3 Ag detected in donor; 2 identical in recipient, third cross 
reactive
B2X 2 donor Ag identical to recipient; 3rd and 4th cross reactive with 
recipient 
C 1 Ag of donor not present in recipient and non cross reactive with 
recipient 
D 2 Ag of donor not present in recipient and non cross reactive with 
recipient
PREVENTION OF ALLOIMMUNITY: -
There is evidence that the leukocytes in the platelet concentrate are responsible for the 
formation  of  HLA  antibodies  than  platelets,  which  can  be  prevented  by  removing  or 
inactivating  class  2  antigens  cells.  To  limit  the  antigenic  exposure,  single  donor  platelet 
transfusion  with  leukocytes  filtered  can  be  used.  By  using  ultraviolet  B  irradiation  blood 
products  can  be  used,  which  prevents  the  interaction  of  dendritic  cells  contained  in  the 
transfusion products with recipient T lymphocytes and reduces the formation HLA antibodies. 
AIM OF THE STUDY
 
 To  evaluate  the  incidence  of  platelet  alloimmunization  in  multiple 
transfused patients.
 To  compare  frequency  of  HLA class  1  antibodies  and  Epitopes  of 
Glycoprotein iib/iiia antibodies in multiple transfused patients.   
MATERIALS AND METHODS
The study was conducted in the Department of transfusion, the Tamil Nadu Dr 
M.G.R medical university, guindy, chennai. 
DESIGN OF THE STUDY: A prospective study. 
PLACE OF COLLECTION:
Blood samples  were collected from Cancer  Institute Adyar and Government general 
Hospital, chennai for a period of 1 year. Detailed history and consent were taken from the 
patients, diagnosis and laboratory detail were taken from the case record.
INCLUSION CRITERIA:
A total of 40 patients who were treated for leukemias, aplastic anemia and lymphomas with 
chemotherapy and multiple transfusions and suspected platelet refractoriness were included in 
this study.      
EXCLUSION CRITERIA:
1. Splenectomized patients.
2. Multiple pregnancies.
3. Received multiple transfusions before.
4. History of drug intake.
5. Positive for HLA class I and Gp iib/iiia epitopes antibodies.
TIME OF COLLECTION:
The first Blood samples were collected before starting first transfusion and Chemotherapy from 
these  patients.  Patients  were  followed  during  therapy  who  was  supported  with  multiple 
Transfusion i.e. more than 10 units of platelets, packed red cell, whole blood and plasma for a  
period of more than 3weeks.  The second blood samples were collected when post transfusion 
platelet count increment is less than 4500 per unit of random donor platelet after 24hr.  
INVESTIGATIONS:   
1) PLATELET COUNT: 
     Platelet count is done by automatic analyzer before and 24hr after transfusion.
2) SEROLOGICAL TESTS:
COMMERCIALLY available ELISA kit (GTI-MACE 1) was used to detect antibodies 
by following manufactures instructions.               
MACE®I  is  a  qualitative  solid  phase  enzyme  linked  immunosorbent  assay  (ELISA) 
designed to  detect  IgG antibodies  to  HLA class  I  antigens  and to  epitopes  on the  platelet 
glycoprotein IIb/IIIa.
PRINCIPLE :
Patient  serum or  plasma  is  incubated  with  intact  platelets  allowing  for  antibody,  if 
present, to bind to the platelet glycoprotein. Unbound antibodies are washed from the platelets. 
The antibody-sensitized platelets are solubilized by the addition of a lysis buffer containing a 
non-ionic  detergent.  The  platelet  lysate  containing  soluble  glycoprotein  is  transferred  to 
microwells. This allows the platelet and HLA class I Glycoprotein (sensitized or unsensitized 
with patient Antibody) to be captured by immobilized monoclonal antibodies. Control Samples 
are handled similarly. After a brief incubation period, unbound Glycoproteins are washed away. 
An alkaline phosphate labeled anti-human Globulin reagent, Anti-IgG is added to the wells and 
incubated.  The Unbound Anti-IgG is  washed away and the substrate PNPP (p nitro phenyl 
Phosphate) is added. After a 30-minute incubation period, the reaction is stopped by a sodium 
hydroxide  solution.  The  optical  density  of  the  color  that  develops  is  measured  in  a 
spectrophotometer. A positive result indicates the presence of glycoprotein-specific antibody on 
the captured GPIIb/IIIa or HLA glycoproteins. 
SPECIEMENT COLLECTION:
SERUM: Blood sample is collected by using aseptic technique and separated serum is stored at 
-20 till  test  is  performed (Samples frozen at  -20°C or below remain in good condition for 
several  years  (2-3  years)).  However,  in  order  to  avoid  the  deleterious  effect  of  repeated 
freeze/thaw cycles, samples are aliquot in small volumes and then stored frozen.   
NOTE:        
Serum or plasma should be separated from red cells when stored or shipped only whole 
human serum or plasma is suitable for this assay. Microbial contaminated, hemolyzed, lipemic 
or heat inactivated samples may give inconsistent test results and should be avoided
METHOD:
Materials provided in the kit:
• 12-1 x 8 Microwell Strips with holder
• 1x 50 mL Concentrated Wash
• 1x 14 mL Specimen Diluents
• 1x 14 mL substrate buffer
• 1x 14 mL Stopping Solution
• 1x 80: L Anti-Human IgG Conjugate
• 6 x 50 mg PNPP Substrate
• 1x 0.7 mL Positive Serum Control
• 1x 0.7 mL Negative Serum Control
• 3 Normal Platelet Controls (50 µL Rehydrate)
• 1x 2.5 mL Cell Lysis Buffer
• 1x 50 mL Cell Resuspension and Preservative Solution
• 12 Plate Sealers
• 2 Recording Sheets
MATERIALS REQUIRED:
1. Test tubes for patient sample, and control dilutions and for reagent dilutions.
2. Transfer pipettes.
3. Adjustable micropipettes to deliver 10 - 100 µl and 100-1,000 µl and disposable 
tips.
4. Timer.
5. Microplate reader capable of measuring OD at 405 or 410 and 490     nm.
6. Absorbent paper towels.
7. Deionized or distilled water.
8. Microplate washer or device.
9. Centrifuge capable of separating serum or plasma from platelets.
10. 37°C water bath or incubator.
11. Micro centrifuge for pelleting platelets.
TEST PROCEDURE:
• All reagents were brought to room temperature.
• Working  Wash  solution  was  prepared  by  diluting  Concentrated  Wash,  1  volume  of 
Concentrated Wash to 9 volumes of deionized or distilled water was added and Mixed 
well.
• The number of patient samples to be tested was determined.
• Using the Recording Sheet, each sample was assigned to a location consisting of one 
well on each strip and the identity of each sample was recorded on the Recording Sheet.
SAMPLES AND CONTROLS PREPARATION:
PREPARATION OF POSITIVE AND NEGATIVE CONTROLS:
One vial of the dried Normal Platelet Control was Rehydrate by adding 400 µmL of Cell 
Resuspension and Preservative  Solution and Allow to stand for  10 to  30 minutes  at  room 
temperature. 
Rehydrate platelets was mixed well and Centrifuge tube to pellet cells. 
Supernatant  was  decant  and  blot  the  tubes  dry.  50  µL of  Cell  Resuspension  and 
Preservative Solution is added to the platelet button and mixed well by pipette to homogenous 
suspension. 
15 µL of the normal platelet suspension was transferred into two clean micro centrifuge 
tubes, and 150u L of Positive Serum Control and negative serum control to each one of the 
tubes and mixed well. Labeled them as positive control and negative control.
PLATELET PREPARATION:
For each platelet sample to be tested, 2 – 3 mL of platelet rich plasma is centrifuged to  
platelet  button.  Supernatant  plasma  was  discarded.  To  the  platelet  button  400  uL of  Cell 
Resuspension and Preservative Solution was added,  mixed well  and Centrifuge to obtain a 
platelet button. Supernatant fluid is discarded. Above steps was repeated for 3 to 4 washes and  
after last wash supernatant was removed, tubes drained with an absorbent paper towel. 
Equal volume of Cell Resuspension and Preservative Solution to the platelet button to 
make 50% homogenous suspension and 15 µL of the 50% platelet suspension was transferred 
to a clean-labeled tube.
PLATELET LYSING:
150 uL of  patient  serum to  be tested is  added to the  tube containing a  platelet  test 
suspension prepared in the previous step and mix well with pipet. Samples and the controls are 
incubated at 37ºC for 40 minutes in dry incubator.
Test and control samples are washed twice by adding 400 uL of Cell Resuspension and 
Preservative Solution to each tube and centrifuging to pellet the platelets.  Supernatant fluid is 
discarded after each wash.  Blot tubes are blot  with absorbent  paper  to remove all  residual  
fluids, with out disturbing the platelet button after final wash.
Note:
Cell  Lysis  Buffer  is  diluted  by  adding  100  µL of  Cell  Lysis  Buffer  to  900  µL of 
deionized or distilled water for each five platelets to be tested. Finally 180 uL of diluted Cell  
Lysis Buffer is added to each test and control tube and mix well with a pipet and vortex for  
complete Lysis.  Platelet lysates are tested 
ELISA FOR DETECTION:
Microwells frame are removed from pouch and strips taken depending upon the test 
numbers and reseal unneeded strips in the protective pouch. Since only one frame is provided 
in the kit frame is used for all tests. The strips, were placed in the frame and marked at the top 
according to Recording Sheet.
50 µL of sensitized platelet lysate, negative control and positive control lysate are added 
to the wells designated on the Recording Sheet leaving blank wells.  The micro wells were 
sealed with a plate sealer and incubate for 40 minutes in a 37°C dry incubator.
Note:
Conjugate is diluted 1 to 100 in Specimen Diluents in a polypropylene container.
After incubation the contents are Aspirate and blot on absorbent toweling.  To this 300-
µL Working  Was  h  solution  is  added in  each well  and  washed.  Above  washing steps  are 
repeated for 3 or 4 times. After final wash remove all residual wash solution by Inverting on 
absorbent toweling to prevent drying.
50 µL of diluted Conjugate was added to all wells except blanks, Seal the microwells 
with a plate sealer and incubate for 40 minutes in a 37°C dry incubator.
Note:
a. PNPP is dissolved in Substrate by adding in 0.5 mL deionized or distilled water to the 
vial and mix well. Protect from light until use.
b. PNPP is diluted 1 to 100 in the Substrate Buffer.
After incubation the contents are Aspirate and blot on absorbent toweling.  To this 300-
µL Working  Was  h  solution  is  added in  each well  and  washed.  Above  washing steps  are 
repeated for 3 or 4 times. After final wash remove all residual wash solution by Inverting on 
absorbent toweling to prevent drying and microwells kept in dark for 30 minutes at RT (22º-
25ºC)
After incubation 100 µL of the diluted PNPP solution to all the wells except blanks. 
Reaction is stopped by adding 100 µL of Stopping Solution to each well in the same sequence 
as the addition of substrate and Add 200 µL of Stopping Solution to the blank wells.
The absorbance (OD) of each well read at 405 or 410 nm using a reference filter of 490 
nm by using automatic ELISA reader and the results were recorded on the Recording Sheet.
RESULT
Of the 40 patients included, 25 were males and 15 were females. The age of the patients 
ranged from 3 to 58yr with a mean of 25.80 and Std Deviation of 19.66. Acute leukemias (30) 
were the main underlying disorders. The others were chronic leukemias (4), aplastic anaemia 
(2)  and lymphoma (4).  The  number  of  blood and/or  blood  components  given to  these  40 
patients ranged from 10- 36 units for the period of more than 3-4 wks. 
                                     TABLE 1       SEX DISTRUBUTION
                              
Sex no of cases Percent
Male 25 62.5
Female 15 37.5
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                                                       TABLE 3   
                                      
                                                      DISEASES
No Underlying disease No of cases HLA/GP positive
1 Acute leukemia 30 5
2 Chronic leukemia 4 1
3 Lymphoma 4 1
4 Aplastic anemia 2 1
 Total 40 8
Total of 40 serum samples were collected from patients who received multiple 
transfusion (minim with 10 units) over a period of 3-4 weeks. showed refractoriness (as 
the platelet count did not increase as expected)  the samples were tested 1)  HLA  and 2) 
GP iib/iiia epitopes antibodies by ELISA (GTI-MACE 1 kit).
Of these      
• 8 patients were positive.
• Five (62.5%) patients were positive for HLA antibodies.
• Two (25%) were positive of GP.
• One (12.5%) patient was positive for both HLA and GP. 
                                     TABLE 4
                                  HLA – GP COMPARETIVE
                                       
                                
                                     FIGURE 3
                            HLA- GP COMPARETIVE
1 5 6
2.5% 12.5% 15.0%
2 32 34
5.0% 80.0% 85.0%
3 37 40
7.5% 92.5% 100.0%
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Sex wise:
Of these 8 patients, 4 were male (4/40) and 4 were female (4/15). HLA antibodies 
was positive in 3 male patients and 2 female patients, were as GP was positive in one of 
each male and female patients. 
One female patient showed positive for both HLA and GP antibodies.
No of transfusion received:
• Total number of units transfused for each patient ranged from 10 to 36.
• 22 patients received 10-15 units of transfusion, of which 2 were positive for HLA and 
one for GP antibodies.
• 9 of  them received  between  15-20  units  of  which  2  were  HLA positive  and 1  GP 
antibodies were positive. 
• 6 patients who received between 20-25 units showed one positive in both HLA and GP. 
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• One patient was positive to HLA antibodies in patients (3) who received more than 25 
units.
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Clinical history
Four female patients of 15 had history of single pregnancy in this. Two out of this study 
group showed positive (1 HLA and 1 GP). 
15 patients had history of fever of which five were positive for antibodies (3HLA, 2GP). 
Out of 40 patients 14 were anemic and four showed HLA and one  GP antibodies. 
Out  of  40  patients  10  had symptom of  jaundice.  4  of  the  jaundice  patients  showed 
positive for antibodies.   
                                            TABLE 7
                                       SIGNS AND SYMPTOMS
 
NO SIGNS/SYMPTOMS
POSITIVE FOR SIGNS 
/SYMPTOMS
HLA/GP 
POSITIVE
1 Fever 15 5
2 Anemia 14 5
3 Jaundice 10 4
4 Lympadenopathy 8 4
5 Splenomegaly 15 6
6 Pregnancy 4 2
DISCUSSION
The aim of this prospective study 
a) To  evaluate  the  incidence  of  platelet  alloimmunization  in  multiple  transfused 
patients.
b) To compare frequency of HLA and GP antibodies.    
This study group consist of 40 patients out of which 8(20%) showed antibodies, In spite 
of the heterogeneity of patients population, treatment, and transfusion.. HLA antibodies were 
detected in 15% (6/40) of  the patients and 7.5% (3/40) of patients were positive for GP iib/iiia  
antibodies who received multiple  blood and platelet  transfusion.  This  study confirmed that 
alloimmunization usually involves HLA antigens than platelet specific antigens. 
The  incidence  of  HLA alloimmunization  in  our  study  is  in  accordance  with  other 
studies. According to Taaning et al 1997 showed in their study that 15% of them who were 
antibodies negative before transfusion, turn out positive for HLA after multiple transfusion. 
Study conducted by Bajpai menu et al 2005; Kiefel v et al 2001 showed higher percentage 
(30%-70%) developed antibodies after multiple transfusion Platelet specific antibodies against 
Gpiib/iiia antigens were found to be Lowe  than HLA  in many studies. Kiefel v et al reported 
45% patients had HLA whereas 8% of patients were HPA positive. Uhrynowska m et al showed 
that 21% had HLA antibodies and than 9% had HPA antibodies. Tanning et al 1997; Bertrand 
Godeau  et  al  1992  studies  showed   that  platelet  specific  antibodies  are  even  lower  than 
5%.These discrepancies could be due to the nature of test methods adopted, the immune status 
of the patients, quality of platelets transfused and basic pathology in patients. In our study only 
one patient showed positive for both HLA and GP antibodies, in contrast to other studies which 
showed more no of cases with both positive. (Lo sc et al 2005 reported 22% had both HLA and 
HPA antibodies.)  
 
Out of 8 patients, five had acute leukemias (ALL-2/23, AML-3/7) and one in each of 
other  disorders  (chronic  leukemias-1/4,  lymphomas  –1/4,  aplastic  anaemia-1/2).  In  acute 
leukemias AML has higher frequency (40%) to that of ALL of 9% in accordance with study 
reported by Docoteau et al 1995.  This difference is due to immunosuppression and altered 
immune status of the disease or immunosuppressive therapy. This may altered the response of 
platelet transfusion. 
Women with the history of single pregnancy (4patients) showed a significantly higher 
incidence of alloimmunization (50%) as compared to patients with no such history. The result 
in this study is in accordance with the study done by Bajpai M et al 2005, states that 83% of the 
women with positive obstetric history had antibodies and 60% with negative history.    
Fever was present in 3 of the patients who were positive for HLA antibodies and 2 GP 
iib/iiia  antibodies  positive  patients  in  this  study  which  were  also  reported  by  Masanoir 
shimoyama et al 1977.  Jaundice and anaemia was seen in more than 50% of the patients who 
are positive for anyone antibody.
In  this  present  study  there  was  no  definite  association  between  the  numbers  of 
transfusions  received during  the  same admission  with  the  development  of  antibodies.  This 
study showed 3 patients who were positive after receiving transfusion between 10-15 units, 3 
between 16-20 units, 1 patient between 21-25 units and 1 patient who received more than 25  
units.  This may be due to smaller number of cases or different donor-patient status. 
Our study brings out a way for the early diagnose of platelet antibodies in multiple 
transfused patients, post transfusion Purpura and neonatal alloimmune thrombocytopenia. With 
suitable modifications, using newer and advance techniques, antibodies can also be detected in 
lower titration levels.
SUMMARY
Incidence of alloimmunization due to HLA class 1 antigens and GP iib/iiia epitopes in 
patients who were transfused with multiple blood and/or blood components had been studied 
and compared with other studies and were found to be less frequency than other studies. 
HLA antibodies were found to be more than GP antibodies and female patients with 
positive pregnancy are more prone to development of refractoriness.
Increased incidence of alloimmunization is seen in AML than ALL.
There  is  no  definite  association  between  the  numbers  of  units  transfused  and  the 
formation of antibodies that leading to refractoriness.
                                CONCLUSION
Our results concluded that multiple random donor blood and platelet transfusion are able 
to induce antibodies against HLA class 1 antigens and epitopes on GP iib/iiia. There was no 
relationship between the number of units transfused and the antibodies formation. Women with 
single pregnancy history were identified as high responder group for alloimmunization. Our 
results show AML are frequently immunized than ALL patients.
Keeping in view the alloimmunization, leukoreduced irradiated single donor platelets 
and blood components should be transfused for the treatment of hematological and oncological 
patients. Till now, non-leukoreduced components are used in most of the centers in India due to 
cost  of  leukoreduction.  Testing  for  the  presence  of  platelet  antibodies  and  transfusion  of 
compatible  platelets  shall  be  important  mode  of  management  and  prevention  of  platelet 
refractoriness in India.     
                   
                   LIMITATIONS OF THE STUDY
• The study period was limited to one year and the number of patients in the study was 
only 40.
• The duration of study is only one year. Long term follow up was not possible as many 
patients were outstationed.   
• The samples were collected only from the oncology patients. .  
• The study method could not be compared with the other methods to find the sensitivity 
and specificity. 
FUTUROLOGY
The  number  of  patients  in  the  study  can  be  increased  and  the  patients  other  than 
oncological disorders can also be included in the study. 
The study can be done for longer period and the patients can be followed upto 1 year by 
testing for antibodies at regular intervals even through transfusions are not given to check for 
disappearance of antibodies. 
The study can be done more specifically by testing individually for antibodies against 
HLA class 1 A and B, HPA 1, 2, 3 and can also be done with other methods to find the best  
method to validate the test.
Female with the history of multiple pregnancies should be studied.
Patients who are receiving single donor platelet and the leukoreduced blood products 
alone can be included in the study to compare the incidence of alloimmunization and efficacy 
of leukoreduction.
This study can also be extended to find out the efficiency of management and prevention 
of alloimmunization by using HLA and HPA matched transfusion.            
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ANNEXURES
PROFORMA
Study:   PLATELET ALLOANTIBODY SPECIFICITIES IN MULTIPLY   TRANSFUSED PATIENTS
Case ID:                                                  DIAGNOSIS:
Age/Sex:
Occupation:
Address:
Short clinical history:
       COMPLAINTS                                            YES                                       NO
1) Gum bleed            :
2) Petechiae/purpura :
3) Hematuria             :
4) Melena                  :
5) Visual disturbance :
6) Fever                      :
7) Arthralgia              : 
    8)  Others                    :
Co morbid Diseases:
     1) HT/DM/PT/CAD/BA                   if yes -
Treatment history:
    1) Drug Intake         ;                                    if yes  -
    2) Surgery                ;                                    if yes  -
    3) Any other illness ;                                    if yes  -
 
Transfusion history:
          Products                                  Date of Tx                         Total no units                         
       a) WHOLE BLOOD   -
       b) PRBC                      -
       c) PLATELETS         -
        d) PLASMA               -
        e) OTHERS                -
 Personal history:
        1) Diet          :                                         veg                                              non-veg
        2) Smoking  :                                          yes                                                no
        3) Alcohol    :                                          yes                                                no
   Pregnancy history:
         No of conceptions           :
         Date of Last delivery       :
                         
  Family History:
1) Bleeding disorders  :                          if yes
2) Malignances            :                          if yes
3)  Contact history         :                          if yes
 Clinical examination
          1) Anemia           :                               yes                                          no
 2) Jaundice         :
          2) Purpura           :                               yes                                          no
          3) Petechia          :                               yes                                          no
          4) Joint swelling;                               yes                                          no
          5) Focal infection:                               yes                                         no
          6) Lympadenopathy:                            yes                                        no
          7) Splenomegaly:                                 yes                                        no
Investigations already done:
                    DATE
1) Hb
2) TC
                    3) DC
4) ESR
       5) Platelet count:
                              DATE OF PLATELET Tx           pre Tx                                post Tx
      6) PT
                   7) BT
                   8) CT
                   9) APTT
    10) Blood grouping
    11) Coomb’s Test
                  12) Special investigations:
Patient Consent: 
 
